Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
780 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00431210 | Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma | completed | Phase 1 | 28 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 18, 2017 | clinicaltrials |
| NCT00856050 | Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma | completed | Phase 2 | 27 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 18, 2017 | clinicaltrials |
| NCT01058655 |
| RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer |
| completed |
| Phase 1 / Phase 2 |
| 56 |
| Dana-Farber Cancer InstituteOTHER |
| 1 |
| Apr 13, 2017 |
| clinicaltrials |
| NCT01551693 | STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma | terminated | Phase 2 | 3 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 12, 2017 | clinicaltrials |
| NCT00005988 | Bone Marrow Transplantation With Specially Treated Bone Marrow in Treating Patients With Hematologic Cancer That Have Not Responded to Previous Therapy | completed | Phase 1 | 5 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 4, 2017 | clinicaltrials |
| NCT00146536 | Upstaging of ALH/LCIS Found on Core Biopsy Based on Subsequent Excisional Biopsy | completed | — | 78 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 31, 2017 | clinicaltrials |
| NCT01065467 | Panobinostat (LBH589) in Patients With Metastatic Melanoma | completed | Phase 1 | 16 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 28, 2017 | clinicaltrials |
| NCT01955395 | Genomic and Psychosocial Effects of the 3RP on Patients With MGUS and Smoldering Multiple Myeloma | completed | N/A | 93 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 16, 2017 | clinicaltrials |
| NCT00545792 | Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers | completed | Phase 2 | 21 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 15, 2017 | clinicaltrials |
| NCT01484314 | Eltrombopag for Thrombocytopenia in Patients With Relapsed Multiple Myeloma | terminated | Phase 2 | 1 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 15, 2017 | clinicaltrials |
| NCT00487513 | Procurement of Follicular B Cell Lymphoma Cells for the Purpose of Possible Use in Future Clinical Trials | completed | — | 40 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 9, 2017 | clinicaltrials |
| NCT01878708 | A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell Lymphoma | terminated | Early Phase 1 | 2 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 6, 2017 | clinicaltrials |
| NCT00101075 | Title XELOX FOR SALIVARY GLAND CANCERS | terminated | Phase 2 | 9 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 27, 2017 | clinicaltrials |
| NCT01562873 | Ruxolitinib in Patients With Breast Cancer | terminated | Phase 2 | 21 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 23, 2017 | clinicaltrials |
| NCT00003761 | Vaccine Therapy in Treating Patients With Metastatic Breast Cancer | completed | Phase 1 | 20 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 15, 2017 | clinicaltrials |
| NCT00003058 | Troglitazone in Treating Patients With Liposarcoma | completed | Phase 2 | 85 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 13, 2017 | clinicaltrials |
| NCT01121718 | NIR-Guided Sentinel Lymph Node Mapping in Melanoma | completed | Phase 1 | 26 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 3, 2017 | clinicaltrials |
| NCT02057432 | Image-guided Breast Surgery in the Advanced Multimodality Image Guided Operating Suite (AMIGO) | completed | N/A | 15 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 24, 2017 | clinicaltrials |
| NCT00003657 | High-dose ICE With Amifostine | completed | Phase 2 | 24 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 20, 2017 | clinicaltrials |
| NCT00003200 | Chemotherapy Plus Radiation Therapy in Treating Patients With Squamous Cell Cancer of the Head and Neck | completed | Phase 1 | 22 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 19, 2017 | clinicaltrials |
| NCT00003744 | Gemcitabine in Treating Patients With Advanced Salivary Gland Cancer That Cannot Be Removed During Surgery | completed | Phase 2 | 16 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 19, 2017 | clinicaltrials |
| NCT02439138 | Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström Macroglobulinemia | terminated | Phase 2 | 5 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 11, 2017 | clinicaltrials |
| NCT00684411 | Gleevec in Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma | completed | Phase 2 | 12 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 5, 2017 | clinicaltrials |
| NCT00095927 | Randomized Amifostine For SCCHN | completed | Phase 2 | 58 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 4, 2017 | clinicaltrials |
| NCT00429910 | Natural History Study of Patients With Chronic Myelogenous Leukemia | completed | — | 48 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 2, 2017 | clinicaltrials |
| NCT00136409 | A Study of Gleevec in Patients With Idiopathic Myelofibrosis or Chronic Myelomonocytic Leukemia (CMML) | completed | Phase 2 | 34 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 23, 2016 | clinicaltrials |
| NCT00251355 | Gemcitabine, 5-Fluorouracil, and Radiation Therapy in the Treatment of Non-Metastatic Pancreatic Cancer | completed | Phase 1 | 40 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 20, 2016 | clinicaltrials |
| NCT00424515 | Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma(BUS255) | completed | Phase 2 | 24 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 8, 2016 | clinicaltrials |
| NCT00577382 | SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma | completed | Phase 2 | 52 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 8, 2016 | clinicaltrials |
| NCT01738438 | Cabozantinib for Metastatic Triple Negative BrCa | completed | Phase 2 | 35 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 6, 2016 | clinicaltrials |
| NCT00165542 | A-protein Levels in Adult and Pediatric Brain Tumor Patients | completed | — | 54 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 23, 2016 | clinicaltrials |
| NCT00874562 | Rapamycin in Relapsed Acute Lymphoblastic Leukemia | completed | Phase 1 | 6 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 23, 2016 | clinicaltrials |
| NCT00378209 | Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma | completed | Phase 2 | 65 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 17, 2016 | clinicaltrials |
| NCT00808639 | Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma | completed | Phase 2 | 39 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 24, 2016 | clinicaltrials |
| NCT00776594 | Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy | completed | Phase 2 | 102 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 21, 2016 | clinicaltrials |
| NCT00852462 | Lung Cancer Symptom Assessment and Management Intervention | completed | Phase 2 | 179 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 21, 2016 | clinicaltrials |
| NCT00804336 | Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors | completed | Phase 1 | 22 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 19, 2016 | clinicaltrials |
| NCT00675831 | Infusion of Donor Lymphocytes Depleted of CD25+ Regulatory T-cells in Patients With Relapsed Hematologic Malignancies | completed | Phase 1 | 24 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 29, 2016 | clinicaltrials |
| NCT00165503 | Pleurectomy/Decortication With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Sodium Thiosulfate | terminated | Phase 2 | 16 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 9, 2016 | clinicaltrials |
| NCT00148694 | Preoperative Cisplatin in Early Stage Breast Cancer | completed | Phase 2 | 27 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 31, 2016 | clinicaltrials |
| NCT01568346 | Breast MRI for Newly Diagnosed Breast Cancer:Impact on Re-excision Lumpectomy | terminated | Phase 3 | 9 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 2, 2016 | clinicaltrials |
| NCT00117156 | Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymphoma | completed | Phase 2 | 26 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 1, 2016 | clinicaltrials |
| NCT02656849 | BAY 1000394 for MCL-1-, MYC-, and CCNE1-Amplified Tumors | withdrawn | Phase 2 | 0 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 1, 2016 | clinicaltrials |
| NCT00153894 | Effects of Exercise Intervention on Insulin Levels in Breast Cancer Survivors | completed | N/A | 100 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 27, 2016 | clinicaltrials |
| NCT00405782 | Exercise Intervention in Women With Metastatic Breast Cancer | completed | N/A | 101 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 27, 2016 | clinicaltrials |
| NCT01978899 | Healthy Living After Cancer: Weight Management Pilot Study | completed | N/A | 60 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 3, 2016 | clinicaltrials |
| NCT00543114 | Dose Escalation Study of Revlimid With Fludarabine-Rituximab for CLL/SLL | terminated | Phase 1 | 9 | Dana-Farber Cancer InstituteOTHER | 1 | May 27, 2016 | clinicaltrials |
| NCT00459186 | The Use of RAD001 With Docetaxel in the Treatment of Metastatic, Androgen Independent Prostate Cancer | completed | Phase 1 / Phase 2 | 19 | Dana-Farber Cancer InstituteOTHER | 1 | May 16, 2016 | clinicaltrials |
| NCT00330252 | Weekly Subcutaneous Alemtuzumab and Rituximab for Relapsed CLL | completed | Phase 1 | 29 | Dana-Farber Cancer InstituteOTHER | 1 | May 13, 2016 | clinicaltrials |
| NCT02689401 | MRI Iron Oxide Imaging for Lymph Node Staging in Esophageal Cancer | withdrawn | Phase 1 | 0 | Dana-Farber Cancer InstituteOTHER | 0 | May 13, 2016 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials